In the News: Research Points to New Possibility for Cholesterol Meds

Monday, September 25, 2017

Recently announced research from Aarhaus University in Denmark may be the first step in making key improvements to cholesterol-lowering medications.

As detailed in the World Pharma News story “Danish Discovery Can Pave the Way for More Effective Cholesterol Medicine,” the university’s researchers have uncovered how LDL receptors are broken down by PCSK9 — a harmful protein that is both formed by the presence of statins and interferes with statins’ effectiveness. The implication, the article notes, is that this knowledge could lead to the development of improved and more cost-effective PCSK9-inhibiting medications to enhance cholesterol treatment.

Without a method of inhibiting its presence, PCSK9 is captured by molecules in the liver, which results in the liver breaking down the LDL receptors necessary to fight bad cholesterol and prevent potential blood clots. The researchers say their discovery sheds more light on how this process occurs, potentially enabling the creation of medicines that more effectively inhibit the problematic protein and reduce cholesterol.

Current PCSK9 inhibitors are extremely costly and only prescribed to high-risk patients. The Danish researchers hope their results will support development of more affordable alternatives.

“The new discovery shows the potential for creating more effective PCSK9 inhibitors than those we have today, and more cheaply, so that they become accessible for many more people in line with statins," says Simon Glerup, associate professor at the Department of Biomedicine at Aarhus University.

Read the full World Pharma News article.

You may also like:

Blog Post

As the U.S. Department of Health and Human Services (HHS) focuses its attention on drug pricing, a pharmacy advocacy group is urging HHS leadership not to ignore the issues presented by direct and indirect remuneration (DIR) fe...

View Blog Post
Blog Post

Patient engagement is defined differently by various clinicians, caregivers, health plans, and other providers. And healthcare organizations can have vastly divergent engagement goals. But one thing the majority of the healthca...

View Blog Post
Blog Post

A recent study sought to quantify the burden of opioid-related deaths in the United States and compare this burden over time and by age and sex.

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up